, Volume 15, Issue 7–8, pp 367–370

Cancers gynécologiques

Compte Rendu / Report

Gynecological cancers


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bonomi P, Blessing JA, Stehman FB, et al. (1985) Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 3(8): 1079–85PubMedGoogle Scholar
  2. 2.
    Burger RA, Brady MF, Bookman MA, et al. (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365(26): 2473–83PubMedCrossRefGoogle Scholar
  3. 3.
    Degenhardt Y, Lampkin T (2010) Targeting Polo-like kinase in cancer therapy. Clin Cancer Res 16(2): 384–9PubMedCrossRefGoogle Scholar
  4. 4.
    Du Bois A, Floquet A, Kim JW, et al. (2013) Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (AEOC): results of an International Intergroup Trial (AGOOVAR16). J Clin Oncol 31(suppl; abstr LBA5503)Google Scholar
  5. 5.
    Jonathan A, Ledermann, Philipp Harter, et al. (2013) Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (SOC) and a BRCA mutation (BRCAm). J Clin Oncol 31(suppl; abstr 5505)Google Scholar
  6. 6.
    Katsumata N, Yasuda M, Takahashi F, et al. (2009) Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomized controlled trial. Lancet 374(9698): 1331–8PubMedCrossRefGoogle Scholar
  7. 7.
    Kehoe S, Hook J, Nankivell M, et al. (2013) Chemotherapy or upfront surgery for newly diagnosed advanced ovarian cancer: results from the MRC CHORUS trial. J Clin Oncol 31(suppl; abstr 5500)Google Scholar
  8. 8.
    Korach J, Colombo N, Davidenko I, et al. (2013) Feasibility and safety of front-line bevacizumab (BEV)-containing therapy after neoadjuvant (NA) chemotherapy (CT) for ovarian cancer (OC): the ROSIA experience. J Clin Oncol (suppl; abstr 5541)Google Scholar
  9. 9.
    Ledermann J, Harter P, Gourley C, et al. (2012) Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 366(15): 1382–92PubMedCrossRefGoogle Scholar
  10. 10.
    Long HJ 3rd, Bundy BN, Grendys EC Jr, et al. (2005) Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol 23(21): 4626–33PubMedCrossRefGoogle Scholar
  11. 11.
    Monk BJ, Sill MW, McMeekin DS, et al. (2009) Phase III trial of four cisplatincontaining doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 27(28): 4649–55PubMedCrossRefGoogle Scholar
  12. 12.
    Pignata S, Scambia G, Lauria R, et al. (2013) A randomized multicenter phase III study comparing weekly versus every 3 weeks carboplatin (C) plus paclitaxel (P) in patients with advanced ovarian cancer (AOC): Multicenter Italian Trials in Ovarian Cancer (MITO-7) — European Network of Gynecological Oncological Trial Groups (ENGOT-ov-10) and Gynecologic Cancer Intergroup (GCIG) trial. J Clin Oncol 31(suppl; abstr LBA5501)Google Scholar
  13. 13.
    Press JZ, De Luca A, Boyd N, et al. (2008) Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 8: 17PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Pujade-Lauraine E, Weber BE, Ray-Coquard I, et al. (2013) Phase II trial of volasertib (BI 6727) versus chemotherapy (CT) in platinum-resistant/refractory ovarian cancer (OC). J Clin Oncol 31(suppl; abstr 5504)Google Scholar
  15. 15.
    Schöffski P, Awada A, Dumez H, et al. (2012) A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours. Eur J Cancer 48(2): 179–186PubMedCrossRefGoogle Scholar
  16. 16.
    Tewari KS, Sill M, Long HJ, et al. (2013) Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group. J Clin Oncol 31(suppl; abstr 3)Google Scholar
  17. 17.
    Thompson DS, Dudley BS, Bismayer JA, et al. (2013) Hainsworth. Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute. J Clin Oncol 31(suppl; abstr 5513)Google Scholar
  18. 18.
    Vergote I, Tropé CG, Amant F, et al. (2010) Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363(10): 943–953PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag France 2013

Authors and Affiliations

  1. 1.Département d’oncologie médicaleCLCC Paul-StraussStrasbourg cedexFrance

Personalised recommendations